Petros Pharmaceuticals (PTPI) Competitors $0.30 -0.01 (-3.25%) As of 03:03 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends PTPI vs. IMNN, HCWB, SNSE, FLGC, AIM, BGXX, HOTH, CRVO, WENA, and CSCIShould you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include Imunon (IMNN), HCW Biologics (HCWB), Sensei Biotherapeutics (SNSE), Flora Growth (FLGC), AIM ImmunoTech (AIM), Bright Green (BGXX), Hoth Therapeutics (HOTH), CervoMed (CRVO), ANEW Medical (WENA), and COSCIENS Biopharma (CSCI). These companies are all part of the "pharmaceutical products" industry. Petros Pharmaceuticals vs. Imunon HCW Biologics Sensei Biotherapeutics Flora Growth AIM ImmunoTech Bright Green Hoth Therapeutics CervoMed ANEW Medical COSCIENS Biopharma Petros Pharmaceuticals (NASDAQ:PTPI) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation, community ranking and profitability. Do insiders and institutionals have more ownership in PTPI or IMNN? 12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 5.0% of Imunon shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate PTPI or IMNN? Imunon has a consensus target price of $20.50, indicating a potential upside of 2,210.12%. Given Imunon's stronger consensus rating and higher probable upside, analysts clearly believe Imunon is more favorable than Petros Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Imunon 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Does the MarketBeat Community believe in PTPI or IMNN? Imunon received 17 more outperform votes than Petros Pharmaceuticals when rated by MarketBeat users. CompanyUnderperformOutperformPetros PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesImunonOutperform Votes18100.00% Underperform VotesNo Votes Which has more volatility & risk, PTPI or IMNN? Petros Pharmaceuticals has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. Comparatively, Imunon has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500. Which has higher valuation and earnings, PTPI or IMNN? Petros Pharmaceuticals has higher revenue and earnings than Imunon. Imunon is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPetros Pharmaceuticals$4.02M0.73-$8.16M-$4.76-0.06Imunon$500K25.74-$19.51M-$1.89-0.47 Does the media prefer PTPI or IMNN? In the previous week, Imunon had 2 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 4 mentions for Imunon and 2 mentions for Petros Pharmaceuticals. Petros Pharmaceuticals' average media sentiment score of 0.71 beat Imunon's score of 0.70 indicating that Petros Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Petros Pharmaceuticals Positive Imunon Positive Is PTPI or IMNN more profitable? Petros Pharmaceuticals' return on equity of -78.22% beat Imunon's return on equity.Company Net Margins Return on Equity Return on Assets Petros PharmaceuticalsN/A -78.22% -23.50% Imunon N/A -230.05%-128.98% SummaryImunon beats Petros Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Petros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTPI vs. The Competition Export to ExcelMetricPetros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.95M$6.56B$5.27B$8.95BDividend YieldN/A2.91%5.07%4.00%P/E Ratio-0.0610.2589.1517.17Price / Sales0.73179.901,153.78127.51Price / CashN/A57.6743.2137.77Price / Book0.074.945.104.99Net Income-$8.16M$153.99M$122.18M$228.48M7 Day Performance-18.98%-4.74%-2.58%-0.85%1 Month Performance-10.58%-2.90%-0.77%1.12%1 Year Performance-77.57%-3.38%24.00%15.90% Petros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTPIPetros Pharmaceuticals0.4915 of 5 stars$0.30-3.3%N/A-76.4%$3.01M$4.02M-0.0620Short Interest ↑Gap UpIMNNImunon2.5083 of 5 stars$0.93+3.2%$20.50+2,107.9%+34.2%$13.46M$500,000.00-0.4930Short Interest ↑Positive NewsGap UpHCWBHCW Biologics1.9319 of 5 stars$0.35-4.9%N/A-71.0%$13.34M$3.50M-0.3540Short Interest ↓News CoveragePositive NewsSNSESensei Biotherapeutics4.4864 of 5 stars$0.53+3.5%$4.33+717.0%-33.8%$13.34MN/A-0.4540Short Interest ↑Gap DownFLGCFlora Growth2.8336 of 5 stars$0.92-4.5%$5.00+445.4%-47.5%$13.23M$64.15M0.00280Short Interest ↓Positive NewsAIMAIM ImmunoTech1.5672 of 5 stars$0.21-3.7%$2.75+1,228.5%-57.6%$13.20M$190,000.00-0.4420BGXXBright GreenN/A$0.07+1.0%N/A-75.3%$13.19MN/A-1.152Gap DownHOTHHoth Therapeutics2.7712 of 5 stars$1.87-1.6%$4.00+113.9%+17.4%$12.91MN/A-1.424Short Interest ↑Gap UpCRVOCervoMed3.3031 of 5 stars$2.04-3.3%$42.00+1,958.8%-75.8%$12.59M$7.14M0.004Short Interest ↓Positive NewsWENAANEW MedicalN/A$0.73-0.5%N/AN/A$12.51MN/A0.00N/AGap UpCSCICOSCIENS BiopharmaN/A$3.28-3.5%N/AN/A$12.33M$7.60M-0.2820Positive NewsGap Down Related Companies and Tools Related Companies Imunon Competitors HCW Biologics Competitors Sensei Biotherapeutics Competitors Flora Growth Competitors AIM ImmunoTech Competitors Bright Green Competitors Hoth Therapeutics Competitors CervoMed Competitors ANEW Medical Competitors COSCIENS Biopharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PTPI) was last updated on 1/15/2025 by MarketBeat.com Staff From Our PartnersStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
